| 0.143 -0.005 (-3.38%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.22 | 1-year : | 0.25 |
| Resists | First : | 0.18 | Second : | 0.22 |
| Pivot price | 0.12 |
|||
| Supports | First : | 0.12 | Second : | 0.09 |
| MAs | MA(5) : | 0.14 |
MA(20) : | 0.13 |
| MA(100) : | 2.13 |
MA(250) : | 4.85 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 67 |
D(3) : | 66.1 |
| RSI | RSI(14): 37.4 |
|||
| 52-week | High : | 13.64 | Low : | 0.08 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABPO ] has closed below upper band by 32.4%. Bollinger Bands are 94.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.15 - 0.15 | 0.15 - 0.15 |
| Low: | 0.11 - 0.11 | 0.11 - 0.12 |
| Close: | 0.15 - 0.15 | 0.15 - 0.15 |
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Wed, 15 Apr 2026
ABPO: Net loss narrowed to $2.9M in 2025, but liquidity and going concern risks remain acute - TradingView
Wed, 15 Apr 2026
Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Wed, 15 Apr 2026
Abpro Holdings (OTC: ABPO) outlines antibody pipeline amid funding strain - Stock Titan
Tue, 31 Mar 2026
Abpro Holdings Delays Annual 10-K Filing - TipRanks
Fri, 20 Feb 2026
Abpro Holdings to be delisted from Nasdaq after failing equity requirement - Investing.com
Wed, 11 Feb 2026
Abpro Holdings receives Nasdaq noncompliance notice, appoints new board members - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 16 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -184.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | -0.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|